Circulating activated immune cells as a potential blood biomarkers of non-small cell lung cancer occurrence and progression

[1]  Jinming Yu,et al.  Increased CD8+CD28+ T cells independently predict better early response to stereotactic ablative radiotherapy in patients with lung metastases from non-small cell lung cancer , 2019, Journal of Translational Medicine.

[2]  Junjie Zhang,et al.  Prognostic Value of White Blood Cells Detected for the First Time After Adjuvant Chemotherapy in Primary Operable Non-Small Cell Lung Cancer , 2018, Technology in cancer research & treatment.

[3]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[4]  K. Zhao,et al.  The prognostic values of tumor-infiltrating neutrophils, lymphocytes and neutrophil/lymphocyte rates in bladder urothelial cancer. , 2018, Pathology, research and practice.

[5]  E. Yorke,et al.  Stereotactic body radiation therapy (SBRT) improves local control and overall survival compared to conventionally fractionated radiation for stage I non-small cell lung cancer (NSCLC) , 2018, Acta oncologica.

[6]  R. Sun,et al.  Tumor immunotherapy: New aspects of natural killer cells. , 2018, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

[7]  F. Askin,et al.  Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy. , 2017, Seminars in cancer biology.

[8]  M. Esteller,et al.  Lung cancer epigenetics: From knowledge to applications. , 2017, Seminars in cancer biology.

[9]  Shuo-chieh Wu,et al.  Predictive Value of CD4+/CD8+ Ratio in Patients with Breast Cancer Receiving Recombinant Human Thrombopoietin. , 2018, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[10]  Ning Li,et al.  Elevated pretreatment neutrophil/white blood cell ratio and monocyte/lymphocyte ratio predict poor survival in patients with curatively resected non‐small cell lung cancer: Results from a large cohort , 2017, Thoracic cancer.

[11]  Hong-wei Shao,et al.  Salvia miltiorrhiza polysaccharide activates T Lymphocytes of cancer patients through activation of TLRs mediated -MAPK and -NF-κB signaling pathways. , 2017, Journal of ethnopharmacology.

[12]  Hongjun Gao,et al.  Predictive value of peripheral regulatory T cells in non-small cell lung cancer patients undergoing radiotherapy , 2017, Oncotarget.

[13]  M. Quer,et al.  Pretreatment count of peripheral neutrophils, monocytes, and lymphocytes as independent prognostic factor in patients with head and neck cancer , 2017, Head & neck.

[14]  Hongwei Zhang,et al.  Low lymphocyte-to-white blood cell ratio and high monocyte-to-white blood cell ratio predict poor prognosis in gastric cancer , 2016, Oncotarget.

[15]  M. Manns,et al.  Tailored Tumor Immunogenicity Reveals Regulation of CD4 and CD8 T Cell Responses against Cancer. , 2016, Cell reports.

[16]  S. Hanash,et al.  The Emerging Role of B Cells in Tumor Immunity. , 2016, Cancer research.

[17]  Yuchen Jiang,et al.  Role of the tumor microenvironment in tumor progression and the clinical applications (Review). , 2016, Oncology reports.

[18]  V. Apostolopoulos,et al.  Eosinophils in Cancer: Favourable or Unfavourable? , 2016, Current medicinal chemistry.

[19]  L. Pusztai,et al.  The Influence of Host Factors on the Prognosis of Breast Cancer: Stroma and Immune Cell Components as Cancer Biomarkers. , 2015, Current cancer drug targets.

[20]  P. Lorenzo-Luaces,et al.  Biomarkers related to immunosenescence: relationships with therapy and survival in lung cancer patients , 2015, Cancer Immunology, Immunotherapy.

[21]  Hongtao Wang,et al.  Imbalance in circulating T lymphocyte subsets contributes to Hu antibody-associated paraneoplastic neurological syndromes. , 2014, Cellular immunology.

[22]  Mingjie Zhu,et al.  Levels of lymphocyte subsets in peripheral blood prior treatment are associated with aggressive breast cancer phenotypes or subtypes , 2014, Medical Oncology.

[23]  Li-hua Sun,et al.  Variation of blood T lymphocyte subgroups in patients with non- small cell lung cancer. , 2013, Asian Pacific journal of cancer prevention : APJCP.

[24]  A. Ghaderi,et al.  Increase of regulatory T cells in metastatic stage and CTLA-4 over expression in lymphocytes of patients with non-small cell lung cancer (NSCLC). , 2012, Lung cancer.

[25]  Gang Zhou,et al.  Cytotoxic Chemotherapy and CD4+ Effector T Cells: An Emerging Alliance for Durable Antitumor Effects , 2012, Clinical & developmental immunology.

[26]  G. Mazzoccoli,et al.  Comparison of circadian characteristics for cytotoxic lymphocyte subsets in non-small cell lung cancer patients versus controls , 2012, Clinical and Experimental Medicine.

[27]  H. Ji,et al.  Finding biomarkers for non-small cell lung cancer diagnosis and prognosis , 2012, Frontiers in Biology.

[28]  T. Strutt,et al.  The potential of CD4 T‐cell memory , 2010, Immunology.

[29]  S. Suwanagool,et al.  Studies on the potential use of CD38 expression as a marker for the efficacy of anti-retroviral therapy in HIV-1-infected patients in Thailand. , 2005, Virology.

[30]  R. Ferris,et al.  Decreased Absolute Counts of T Lymphocyte Subsets and Their Relation to Disease in Squamous Cell Carcinoma of the Head and Neck , 2004, Clinical Cancer Research.